A single-center, single-arm, phase 2 trial assessed the activity and safety of a combination of humanized anti-CD19 and anti-BCMA CAR T cells in patients with R/R MM and confirmed that this combined infusion is feasible with ORR of 95% and CRR of 43%.450 As for AML, CAR-T therapy seems to be less effective due to the lack of appropriate tumor targets and is still being explored in preclinical and clinical studies.289,451–453 The difficulty of manufacturing cell products using autologous T cells is the major problem facing CAR-T therapy in T-ALL. This evidence concerns the gene CD19 and Miyoshi myopathy.